J-M L'Orphelin, J Cassecuel, L Kandolf, C A Harwood, P Tookey, M H Junejo, S Hogan, C Lebbé, Z Appalla, T-M Kränke, G Pellacani, D Cerasuolo, B Dujovic, V Del Marmol, A Forschner, C Garbe, V Bataille, J M Ressler, P Sollena, A Dompmartin, K Peris, B Dreno
BACKGROUND: Checkpoint inhibitors provide an effective approach for the melanoma treatment. They prolong lymphocyte effects, which explains the cytotoxicity underlying immune-related adverse events (IrAEs). Cutaneous IrAEs affect nearly 40% of PD-1i and 50% of CTLA4i-treated patients. Severe cutaneous irAE do not often occur but could be life-threatening and may persist despite treatment discontinuation. METHODS: We aimed to investigate cutaneous IrAEs in a cohort of patients treated with ICI across Europe in an effort to characterize the reactions in a real-world, phase IV, post-marketing study using a follow-up questionnaire...
April 12, 2023: Journal of the European Academy of Dermatology and Venereology: JEADV